Ratings Ion Beam Applications, SA

Equities

IBAB

BE0003766806

Advanced Medical Equipment & Technology

Market Closed - Euronext Bruxelles Other stock markets 11:35:05 2025-02-14 am EST			5-day change	1st Jan Change
13.90 ^EUR	+1.02%		+3.12%	+3.58%

Feb. 07	Ion Beam Applications, Framatome Partner to Produce Cancer Therapy Radioisotope	MT
Feb. 07	Framatome, IBA To Partner To Develop An Astatine-211 Cyclotron Network	RE

Summary: Ion Beam Applications, SA

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Highlights: Ion Beam Applications, SA

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 43% by 2026.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
With regards to fundamentals, the enterprise value to sales ratio is at 0.84 for the current period. Therefore, the company is undervalued.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Historically, the company has been releasing figures that are above expectations.

Weaknesses: Ion Beam Applications, SA

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 60.43 times its estimated earnings per share for the ongoing year.
The company appears highly valued given the size of its balance sheet.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings Chart: Ion Beam Applications, SA

Source: Surperformance

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals	Valuation	Revisions of Fundamental Estimates	Capi.($)
	ION BEAM APPLICATIONS, SA				426M
	INTUITIVE SURGICAL, INC.				212B
	THERMO FISHER SCIENTIFIC INC.				203B
	BOSTON SCIENTIFIC CORPORATION				156B
	DANAHER CORPORATION				148B
	SIEMENS HEALTHINEERS AG				67.37B
	EDWARDS LIFESCIENCES CORPORATION				44.94B
	SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.				43.65B
	GE HEALTHCARE TECHNOLOGIES INC.				42.17B
	AGILENT TECHNOLOGIES, INC.				38.42B
	Average				95.75B
	Weighted average by Cap.

See all sector ratings

Investor

Trader

ESG MSCI

Financials

Sales growth

EPS Growth

Profitability

Net margin

Financial Health

Valuation

P/E ratio

EV/REVENUE

EV/EBITDA

PBR

Yield

Revisions

1 year Revenue revision

4 months Revenue revision

1 months Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analysts' recommendations

4m Revision of opinion

Potential Price Target

4m Target Price Revision

12m Target Price Revision

Business Predictability

Earnings quality

Analyst Coverag

Divergence of analysts' recommendations

Divergence of Target Price

Divergence of analysts' opinions

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes